Skip to main content

Table 1 Patient characteristics

From: A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients

Demographic Covariates Categorical n (%)
Tumor Type
 NSCLC all types 158 (71.5)
  Non-Squamous 96
  Squamous 42
  Unknown NSCLC type 20
 Melanoma 48 (21.7)
 RCC 14 (6.3)
 Mesothelioma 1 (0.5)
Treatment
 Nivolumab monotherapy (3 mg/kg Q2W) 221 (100)
Gender
 Male 138 (62.4)
 Female 83 (37.6)
Race
 Caucasian 195 (88.2)
 Other 5 (2.3)
 Unknown 21 (9.5)
WHO Performance Status  
 0 63 (28.5)
 1 103 (46.6)
 2 4 (1.8)
 Unknown 51 (23.1)
Weight loss prior to start therapy (only in NSCLC)
 Yes 36 (16.3)
 No 81 (36.7)
 Unknown 104 (47.1)
Demographic and Laboratory Covariates Continuous Median (IQR) n (%)
 Age (yr) 65 (59–71) 221 (100)
 Body Weight (kg) 78.5 (70–88) 220 (99.5)
 Body Surface Area (m2) 1.95 (1.81–2.09) 205 (93)
 Tumor Burden 3D (cm3; only in NSCLC) 18.6 (66–98) 25 (11)
 Creatinine (μmol/L) 81 (66–98) 203 (92)
 CKD (mL/min) 81 (62–90) 203 (92)
 Total Protein (g/L) 73 (69–90) 163 (74)
 Albumin (g/L) 42 (42–45) 174 (79)
 LD (U/L) 215 (183–275) 196 (89)
 Leucocytes (109 cells/L) 7.7 (6.3–10.2) 203 (92)
  1. Baseline covariates of patients
  2. Abbreviations: n number of patients, IQR inter-quartile range, CKD CKD-EPI renal clearance, LD lactate dehydrogenase